Biophysical characterization of binary and ternary drug-target complexes using the Bruker SPR-32 Pro platform

The pharmaceutical industry is constantly seeking innovative strategies for drug discovery and development. A key aspect of this endeavor is gaining a deeper understanding of the molecular interactions between drug candidates and their target proteins. This knowledge helps researchers not only identify promising leads but also optimize them for cellular and in vivo efficacy.

This on-demand webinar showcases the use of biophysical techniques like SPR (Surface Plasmon Resonance) and X-ray crystallography to characterize drug-target interactions.

• Gain comprehensive insights into the molecular mode of target modulation
• Explore how compound properties seamlessly translate into cellular and in vivo efficacy of drug candidates

Drug discovery labs need to characterize the structure activity relationship of their candidate molecules and gain insights in the mechanism of action. The webinar will focus on the in-depth characterization of screening hits' interaction with target proteins, covering aspects such as activity, affinity, binding kinetics, thermodynamics, and their ability to modulate protein conformations and dynamics. This knowledge plays a pivotal role in diversifying early hit matter and optimizing drug candidates in pre-clinical research programs.

This webinar is perfect for drug discovery scientists and researchers, biochemists and biophysicists, and or anyone interested in the latest advancements in drug development.

Watch this free on-demand webinar now and accelerate your drug discovery journey!

Key takeaway:

• Support of Hit ID and Hit characterization in early drug discovery through biophysical methods
• Case studies showcasing assay development for binary and ternary complex formation
• Applications of the Bruker SPR-32 PRO Platform for gaining insights into binding affinities and kinetics for small (NCE) and large (NBE) binders
• SPR method development to support kinetic characterization of challenging drug targets directly from cellular extracts